Intravitreal dexamethasone implant for a vitrectomized eye with diabetic macular edema

A 71-year-old man suffered from diabetic vitreous hemorrhage in his left pseudophakic eye. He received 20-gauge pars plana vitrectomy and removal of taut posterior hyaloid traction in June 2011. Spectral-domain optical coherence tomography demonstrated cystoid macular edema 1 month after the operation. The macular edema did not respond to macular grid laser. Intravitreal bevacizumab (1.25 mg) was injected, which was effective for managing diabetic macular edema initially. The edema recurred 3 months following the bevacizumab injection. Subsequent intravitreal triamcinolone 1 mg also failed to treat the macular edema. Ozurdex, a dexamethasone implant, was injected intravitreally in January 2012. The central foveal thickness decreased, and visual acuity improved. The effect persisted for 6 months. There was no systemic or ocular adverse event during the follow-up period. This intravitreal dexamethasone implant could be helpful for diabetic macular edema in vitrectomized eyes.